Preview

Нефрология

Расширенный поиск

КАРДИОПРОТЕКТИВНАЯ ТЕРАПИЯ БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК

https://doi.org/10.24884/1561-6274-2007-11-3-21-28

Полный текст:

Об авторах

О. Б. Кузьмин
Оренбургская государственная медицинская академия
Россия
кафедра фармакологии


М. О. Пугаева
Оренбургская государственная медицинская академия
Россия
кафедра фармакологии


Список литературы

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 [Suppl 12]: S16-S23

2. Excerpts from the United States Renal Data System’s 2000 Annual Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2000; 36 [Suppl 2]: S1-S137

3. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of the death, cardiovascular events and hospitalization. N Engl J Med 2004; 351 (13): 1296-1306

4. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a factor for development of cardiovascular disease: a statement from the American heart association, councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, epidemiology and prevention. Circulation 2003; 108 (17): 2154-2169

5. Карабаева АЖ, Каюков ИГ, Есаян АМ, Смирнов АВ. Ренин-ангиотензин-альдостероновая система при хронической болезни почек. Нефрология 2006; 10 (4): 43-47

6. Кузьмин ОБ. Хроническая болезнь почек и состояние сердечно-сосудистой системы. Нефрология 2007; 11 (1): 28-37

7. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients. Hypertension 2005; 45 (2): 198-202

8. Olsen MH, Wachtell K, Ibsen H et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24 (4): 775-781

9. de Zeeuw D, Remuzzi G, Parving H-H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110 (8): 921-927

10. Chobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42 (6): 1206-1252

11. Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-1053

12. National Kidney Foundation: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 [Suppl 1]:S1-S290

13. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 [Suppl 3]: S49-S57

14. Pohl M, Blumenthal S, Cordonnier D et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial (IDNT): clinical implications and limitations. J Am Soc Nephrol 2005; 16 (10): 3027-3037

15. Berl T, Hunsicker L, Lewis J et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005; 7 (10): 2170-2179

16. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 2006; 21 (5): 1257-1262

17. Weiner DE, Tighiouart H, Levey AS et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007; 18 (3): 960-967

18. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Result of the survival and enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327 (3): 669-677

19. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342 (8875): 821-828

20. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная недостаточность 2007; 8 (1): 4-41

21. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan in Acute Myocardial Infarction Trial Investigators: valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003; 349 (19): 1893-1906

22. McKelvie RS, Yusuf S, Pericak D et al. Comparison cadesartan, enalapril and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study.Circulation 1999; 100 (8): 1056-1064

23. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial – The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 360 (9215): 752-760

24. Danchin N, Cucherat M, Thuillez C et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006; 166 (7): 787-796

25. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-869

26. Berl T. Hunsicker LG, Lewis JB et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138 (7): 542-549

27. Solomon SD, Rice MM, Jablonski K et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114 (1): 26-31

28. Tokmakova MP, Skali H, Kenchaih S et al. Chronic kidney disease, cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival and Ventricular Enlargement (SAVE) study. Circulation 2004; 110 (24): 3667-3673

29. Nakamura T, Kanno Y, Takenaka T, Suzuki H. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res 2005; 28 (5): 415-423

30. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of randomized trial for future studies. Kidney Int 2006; 70 (7): 1318-1324

31. Berger AK, Duval S, Manske C et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153 (6): 1064-1073

32. Takanashi A, Takase H, Toriyama T et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic hemodialysis: a randomized study. Nephrol Dial Transplant 2006; 21 (9): 2507-2512

33. Locatelli F, Covic A, Chazot C et al. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19 (5): 1058-1068

34. Black HP, Sica DA. Modern perspective of beta-blockers use in hypertension: clinical trials and their influence on clinical practice. J Clin Hypertens (Greenwich)2007; 4 [Suppl 4]: 10-18

35. Domanski MJ, Krause-Steinrauf H, Massie BM et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF and COPERNICUS. J Card Fail 2003; 9 (5): 354-363

36. Беленков ЮН. Современные подходы к лечению ХСН. Серд недостаточность 2001; 2 (1): 6-7

37. Кузьмин ОБ, Пугаева МО, Жежа ВВ. Нефропротективная терапия гипертензивных больных с хронической болезнью почек: есть ли в ней место для β-адреноблокаторов третьего поколения и агонистов I 1-имидазолиновых рецепторов? Нефрология 2006; 10 (2): 18-27

38. Bakris GL, Fonseca V, Katholi RE et al. Differential effects of в-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46 (6): 1309-1315

39. Chonchol M, Goldenberg I, Moss AJ et al. Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol 2007; 27 (1): 7-14

40. Foley RN, Herzog CA, Collins AG. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int 2002; 62 (5): 1784-1790

41. Abbot KC, Trespalacios FC, Agodoa LY et al. в-Blockres use in long-term dialysis patients. Arch Intern Med 2004; 164 (22): 2465-2571

42. Синозерская ВА, Назаренко ЕА, Бородулина ЛА. Оценка влияния терапии карведилолом на сердечно-сосудистую систему у пациентов на программном гемодиализе. Нефрология 2006; 8 (3): 259-261

43. Nakayama M, Ishii A, Takequchi F, Nakano H. Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction. J Cardiol 2006; 47 (6): 285-291

44. Cice G, Ferrara L, D’Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. A prospective, placebo-controlled trial.J Am Coll Cardiol 2003; 41 (9): 1438-1444


Для цитирования:


Кузьмин О.Б., Пугаева М.О. КАРДИОПРОТЕКТИВНАЯ ТЕРАПИЯ БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК. Нефрология. 2007;11(3):21-28. https://doi.org/10.24884/1561-6274-2007-11-3-21-28

For citation:


Kuzmin O.V., Pugaeva M.O. CARDIOPROTECTIVE THERAPY OF PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology (Saint-Petersburg). 2007;11(3):21-28. (In Russ.) https://doi.org/10.24884/1561-6274-2007-11-3-21-28

Просмотров: 62


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)